Smith & Nephew PLC (LSE:SN.) shares fell 2.64% to 982.40p at the close on Thursday, 1 October 2026, a decline of 26.60p from the previous close of 1,009p. The medical technology group dropped below the 1,000p mark as the FTSE 100 recorded its sharpest daily decline since May.
The fall leaves Smith+Nephew with a Market Capitalisation of approximately £8.45 billion.
Key Highlights
Smith+Nephew reported underlying Revenue growth of 2.3% in the first half of 2026, with reported revenue growth of 4.6% helped by a 230 basis point foreign exchange tailwind.
Trading profit rose 8.1% to $566 million, and the trading profit Margin improved 60 basis points to 18.3%.
Operating profit increased 4.3% to $448 million, with the Operating Margin flat at 14.5%.
The company realised $130 million of efficiency savings in the first half, and Tariff refunds fully offset the expected tariff headwind.
However, Smith+Nephew cut its full-year revenue growth guidance to around 4% from around 6%, while keeping its trading profit, free Cash Flow and adjusted ROIC guidance unchanged.
About Smith & Nephew PLC
Smith & Nephew PLC (LSE:SN.) is a global medical technology Business headquartered in Watford, England.
It operates through three main franchises: Orthopaedics, including hip and knee implants and robotics; Sports Medicine & ENT, covering joint repair and ear, nose and throat procedures; and Advanced Wound Management, including dressings, devices and bioactives.
The company has been executing its 12-Point Plan, a programme designed to improve productivity, profitability and growth, particularly in its orthopaedics business.
Why Is LSE:SN. Down Today?
The 2.64% decline to 982.40p came as Global Bond yields surged. The UK 30-year gilt Yield rose above 6% for the first time since 1998, and US Treasury yields climbed to their highest levels in more than two decades.
Healthcare stocks are often seen as defensive, but higher discount rates can still weigh on their valuations, particularly where investors are paying for an expected recovery in growth and margins.
For Smith+Nephew, the reduced revenue guidance means investors are relying on a strong second-half step-up, which can make sentiment more fragile when markets turn risk-off.
Key Reasons Behind the Downtick
The first Factor is valuation pressure from rising yields, which affected defensive and Growth Stocks across the market.
The second is the revenue guidance cut. Full-year revenue growth expectations were reduced to around 4%, reflecting a softer-than-expected first half.
Third, the plan relies on a second-half acceleration, with revenue growth expected at 5.0% to 5.5%, helped by factors including an extra trading day in the fourth quarter.
Fourth, Advanced Wound Management faced reimbursement changes in skin substitutes, which slightly reduced its margin to 22.0%.
How the Wider Market Moved
The FTSE 100 lost 177.73 points to close at 10,428.27, its fourth consecutive daily decline. While banks led the sell-off, healthcare and consumer staples also fell, with Haleon and Unilever among other defensive names under pressure.
Smith+Nephew's decline was in line with the broader market rather than a sharp company-specific move, suggesting the selling reflected macro conditions rather than new information about the business.
Key Growth Catalysts
The strongest catalyst for LSE:SN. is margin improvement. The 12-Point Plan has made the group more resilient, as shown by strong trading profit growth despite softer revenue.
Sports Medicine & ENT is a key growth area, with its trading profit margin up 160 basis points to 24.7% thanks to strong revenue growth.
New product launches in Orthopaedics, along with the Acquisition of Integrity Orthopaedics, could support future growth. Management expects increased LEGION MS set deployments in the second half.
Unchanged guidance for trading profit, free cash flow and return on invested capital underpins the Earnings outlook.
Risks
The main risk is execution. If revenue growth does not accelerate in the second half, the group could face pressure on its guidance.
Reimbursement changes, tariffs, competition in orthopaedics and currency movements are further considerations.
Healthcare procedure volumes and hospital budgets can also affect demand.
Valuation
At 982.40p, LSE:SN. has a Market Value of around £8.4 billion. The valuation reflects a business in a recovery phase, with improving margins but slower-than-hoped revenue growth.
Investors appear to be waiting for evidence that the second-half acceleration can be delivered before rewarding the profit improvement.
What Investors Should Watch Next
The Q3 2026 trading update will show whether revenue growth is accelerating towards the 5.0% to 5.5% second-half target.
Investors will watch orthopaedics performance, LEGION MS deployments and further progress on efficiency savings.
Developments in wound care reimbursement and tariffs will also be important.
Overall, LSE:SN.'s 2.64% decline to 982.40p reflects market-wide pressure and lingering caution after the revenue guidance cut. Smith+Nephew continues to deliver strong profit growth and margin improvement, but needs to show stronger sales momentum.






Please wait processing your request...